Journal profile · Dermatology
Melanoma Research
ISSN 0960-8931 · eISSN 1473-5636 · Lippincott Williams and Wilkins Ltd. · UNITED STATES · Bimonthly · Founded 1991
Melanoma Research: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.83; JCR Q3 (journal website); hybrid open access; median 84 days to acceptance (57 articles, last 24 months); community-reported acceptance: fairly easy; 56 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Melanoma Research is published by Lippincott Williams and Wilkins Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways and Immunotherapy and Immune Responses, together about 50.3% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Melanoma Research is a well established international forum for the dissemination of new findings relating to melanoma. The aim of the Journal is to promote the level of informational exchange between those engaged in the field. Melanoma Research aims to encourage an informed and balanced view of experimental and clinical research and extend and stimulate communication and exchange of knowledge between investigators with differing areas of expertise. This will foster the development of translational research. The reporting of new clinical results and the effect and toxicity of new therapeutic agents and immunotherapy will be given emphasis by rapid publication of Short Communications. Thus, Melanoma Research seeks to present a coherent and up-to-date account of all aspects of investigations pertinent to melanoma. Consequently the scope of the Journal is broad, embracing the entire range of studies from fundamental and applied research in such subject areas as genetics, molecular biology, biochemistry, cell biology, photobiology, pathology, immunology, and advances in clinical oncology influencing the prevention, diagnosis and treatment of melanoma.
Source: LetPub
Research area (LetPub): Dermatology
Editor-in-chief F.J. LejeunePublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cutaneous Melanoma Detection and ManagementMedicine27.2%
- Melanoma and MAPK PathwaysBiochemistry, Genetics and Molecular Biology13.2%
- Immunotherapy and Immune ResponsesImmunology and Microbiology9.9%
- melanin and skin pigmentationBiochemistry, Genetics and Molecular Biology6.1%
- Cancer Immunotherapy and BiomarkersMedicine5.2%
- CAR-T cell therapy researchMedicine5.1%
- Nonmelanoma Skin Cancer StudiesMedicine4.1%
- Cell Adhesion Molecules ResearchMedicine3.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Dermatology | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Dermatology | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Dermatology | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q3 · DERMATOLOGY · rank 61/99
- JCR Q3 · MEDICINE, RESEARCH & EXPERIMENTAL · rank 136/191
- JCR Q4 · ONCOLOGY · rank 264/333
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.83LetPub ·
- Impact factor (publisher)
- 1.8Publisher website ·
- CiteScore 2026-06
- 3.1LetPub ·
- SJR 2026-06
- 0.74LetPub ·
- SNIP 2026-06
- 0.51LetPub ·
- h-index
- 67LetPub ·
- h-index
- 96OpenAlex ·
- i10-index
- 1,812OpenAlex ·
- 2-year mean citedness
- 1.9OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 22.34%LetPub ·
Volume
- Articles per year
- 55LetPub ·
Articles by year OpenAlex count · 5,297 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 63 | 14 | 16 |
| 2025 | 56 | 13 | 75 |
| 2024 | 69 | 23 | 267 |
| 2023 | 78 | 29 | 405 |
| 2022 | 74 | 16 | 525 |
| 2021 | 81 | 25 | 693 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
84 daysMedian, submission to acceptance · P25–P75 44 days – 137 days
- Acceptance to online
- median 34 days (57 articles)
- Submission to online
- median 130 days
- Sample
- 57 articles with submission and acceptance dates (138 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Lippincott Williams and Wilkins Ltd.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1991
- ISSN
- 0960-8931
- Electronic ISSN
- 1473-5636
- Latest issue on the website
- Volume 36, Issue 5 (October 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
FAQ
Frequently asked questions about Melanoma Research
What CAS zone is Melanoma Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Melanoma Research is in Zone 4 of Medicine, and in Zone 4 of the minor category Dermatology / Medicine, Research & Experimental / Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Melanoma Research?
The latest impact factor listed by LetPub is 1.83; CiteScore 3.1, h-index 96.
How long does peer review take at Melanoma Research?
Based on the dates recorded on 57 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 84 days (interquartile range 44–137 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Melanoma Research in?
The journal's website gives JCR Q3; by category, DERMATOLOGY Q3 (61/99), MEDICINE, RESEARCH & EXPERIMENTAL Q3 (136/191), ONCOLOGY Q4 (264/333). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 4 of Medicine.
Which databases index Melanoma Research?
According to LetPub and DOAJ records, Melanoma Research is indexed in SCIE and Scopus.
Is Melanoma Research open access, and what is the APC?
Melanoma Research is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .